U.S. should review drugmakers’ opioid settlement tax breaks – House panel

FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

WASHINGTON – The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a statement on Monday.

The lawmakers, in a letter dated March 10, asked the departments to examine the tax breaks taken by Cardinal Health Inc, McKesson Corp, AmerisourceBergen Corp and Johnson &Johnson.

(Reporting by Susan Heavey; Editing by Katharine Jackson)

Related posts

Meet Cracker Barrel’s Chief Marketing Officer Who Made the Decision to Rebrand the Company, Causing $100 Million in Losses

Majority of New Jersey Residents are Struggling Financially According to Poll

New Jersey Files Charges Against GOP Chairman Over $382 Tax Fraud